ClinicalTrials.gg
RecruitingNCT07048327TJ IntrauterinUpdated Jul 2, 2025

Cohort Study of Intrauterine Diseases

An observational study in Endometrial Cancer, Endometrial Hyperplasia and Endometrial Polyps, sponsored by Wenwen Wang. Recruiting at 1 site in China. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by Wenwen Wang · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 172 studies in Endometrial Neoplasms with a site in China — 100 open to participants now, 122 under way, 21 of them phase 3. Endometrial Neoplasms · China.

Planned enrollment
11th of 30
2,000 · median 840
Started
2025
with 29 others
Observational
30 of 172
11 open now
Primary completion
2028-07
later than 95 of 121 live
Registered
139th of 172
by date

Among the 172 studies in Endometrial Neoplasms with a site in China, this one is the 11th largest by planned enrollment of the 30 observational ones that give a count, is one of 30 that started in 2025, is one of 30 observational ones, reaches primary completion later than 95 of the 121 other live ones, and was the 139th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

100 of the 172 studies in Endometrial Neoplasms with a site in China are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 172 studies in Endometrial Neoplasms with a site in China, or all of them as a file.
02

Study summary

"This study employs a prospective cohort design by establishing a uterine cavity diseases research platform. The investigators will collect participants' current medical history, menstrual and obstetric history, past medical history, physical and gynecological examinations, imaging studies, laboratory tests, and pathological examinations. After the hysteroscopic surgery, the investigators will conduct a one-year follow-up on the disease progression of the participants. Through this comprehensive approach, the investigators aim to deeply investigate the pathogenesis, risk factors, and optimized treatment strategies for uterine cavity diseases."

Read the detailed description

Uterine cavity diseases are a common category of hormone-dependent gynecological conditions, encompassing a wide spectrum from benign lesions to malignant tumors, including endometrial hyperplasia, endometrial polyps, and endometrial malignancies.

Endometrial hyperplasia is classified into two types: hyperplasia without atypia and atypical hyperplasia. Atypical hyperplasia is considered a precancerous lesion of endometrial malignancies, which may lead to irregular vaginal bleeding, menstrual disorders, and carries the risk of malignant transformation. Endometrial polyps, a common benign lesion within the uterine cavity, often cause abnormal uterine bleeding, infertility, or recurrent miscarriages, significantly impacting women's reproductive health and quality of life. Endometrial malignancies, the most prevalent malignant tumors in the female reproductive system, pose a serious threat to women's lives and safety. These diseases not only profoundly affect women's physical health but also have far-reaching negative consequences on their mental well-being, social functioning, and overall quality of life.

In light of this, this study aims to utilize patients' clinical data resources to establish a cohort research platform for uterine cavity diseases, bridging the gap between clinical practice and scientific research, and providing valuable clinical data resources for in-depth studies on these conditions.

03

Conditions studied

  • Endometrial Cancer
  • Endometrial Hyperplasia
  • Endometrial Polyps

Keywords

  • Intrauterine diseases
  • Endometrial Cancer
  • Endometrial Hyperplasia
  • Endometrial Polyps
  • Cohort Study
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study Population will be enrolled by a multicenter study led by Tongji Hospital , in collaboration with over 30 tertiary hospitals. Patients requiring hysteroscopic or curettage procedures for intrauterine lesions such as endometrial hyperplasia, polyps, and malignancies will be recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-80 years;
  • Patients requiring hysteroscopy or diagnostic curettage for intrauterine pathologies (e.g., endometrial hyperplasia, endometrial polyps, submucosal uterine fibroids, adenomyosis, or endometrial );
  • Willing and able to comply with follow-up requirements;
  • Signed obtained.

Exclusion criteria

Exclusion Criteria:

  • Concurrent participation in other drug clinical trials;
  • to or inability to tolerate hysteroscopy/curettage procedures;
  • Unwilling or unable to provide ;
  • Unwilling or unable to adhere to study protocols.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Intrauterine Diseases Cohort

    Disease-specific cohort for uterine cavity diseases

    Other: No intervention (observational study)

Interventions

  • OtherNo intervention (observational study)

    No intervention (observational study)

06

What researchers measure

Primary outcomes

  1. The recurrence of endometrial polyps or endometrial hyperplasia.

    To evaluate the presence of disease progression and recurrence through imaging results.

    Time frame: Follow up every three months for one year after hysteroscopic surgery

07

Study locations

1 of 1 sites recruiting
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430000, China
    Recruiting
    • Pu Zhou · Contacttongjihlunli@163.com · +86-027-83662379
    • Wen W Wang, Dr. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data cannot be shared due to ethical restrictions and participant privacy protections outlined in the informed consent documents.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Jul 2028, 36 months later.

Of 130 non-industry observational studies under Endometrial Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 206. This study's planned 36 months is below that.

Counting every sponsor, half of 150 studies reached it within 105 months; a quarter within 32 and three quarters within 206.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2025
First posted
Jul 2, 2025
StartEst.
Jul 2025
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07048327
Lead sponsor
Wenwen Wang
Responsible party
Wenwen Wang (Clinical Professor, Tongji Hospital) — Sponsor-investigator
First posted
Jul 2, 2025
Start date
Jul 2025 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Jul 2, 2025

Study contacts

Wen W Wang, Dr.
Contact
petrawang@163.com
+86 15927167698

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion